IPO News Archive
Biopharmaceutical company Omeros files for an IPO

1/9/08


Omeros, a clinical-stage biopharmaceutical company focused on inflammation and disorders of the central nervous system, filed with the SEC for an IPO on Wednesday. Deutsche Bank is the lead manager on the deal. The company has applied to have their common stock listed on the NASDAQ under the ticker OMER. No terms were disclosed in the initial filing.

View IPO Profile: OMER         
Related Links: Recently Filed IPOs
Source: www.RenaissanceCapital.com
Latest User Comments

Attribution Policy: The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital, Greenwich, CT (www.renaissancecapital.com).
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital and/or the IPO Plus Fund (symbol: IPOSX) may have investments in securities of companies mentioned.
Invest in the IPO Plus Fund
About Fund Prospectus Invest